Longitudinal Pancreatic Cancer Study
NCT02250638 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140
Last updated 2021-08-17
Summary
To obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of pancreatic cancer.
Conditions
Interventions
- OTHER
-
CA 19-9 Assay
Physicians use the CA 19-9 test results to manage their patients
Sponsors & Collaborators
-
Fujirebio Diagnostics, Inc.
lead INDUSTRY
Principal Investigators
-
Diana Dickson · Fujirebio Diagnostics, Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-05-31
- Primary Completion
- 2021-06-30
- Completion
- 2021-06-30
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Pancreatic Cancer Serum and DNA Repository
NCT00296114 ·Status: COMPLETED
-
Pancreatic Cancer Collaborative Registry
NCT00661882 ·Status: COMPLETED
-
Identification of Biomarkers for Early Detection of Pancreatic Cancer
NCT00897494 ·Status: COMPLETED
-
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
NCT06271291 ·Status: RECRUITING
-
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
NCT05287347 ·Status: WITHDRAWN
-
Project Survival-Prospective Biomarker Discovery
NCT02781012 ·Status: UNKNOWN
-
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
NCT02869802 ·Status: RECRUITING
-
Early Detection of Pancreatic Cancer
NCT05596435 ·Status: UNKNOWN
-
Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants
NCT00898482 ·Status: COMPLETED
-
Studying Biomarkers in Patients With Pancreatic Cancer
NCT00900003 ·Status: COMPLETED
-
Pilot Study of Pancreatic Cancer Screening
NCT05058846 ·Status: RECRUITING
-
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer
NCT06947382 ·Status: COMPLETED
-
Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.
NCT06397846 ·Status: RECRUITING ·Phase: NA
-
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
NCT05132504 ·Status: RECRUITING ·Phase: PHASE2
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT02000089 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
NCT00245362 ·Status: COMPLETED ·Phase: PHASE2
-
Collection of Circulating Biomarkers in Pancreatic Cancer
NCT05743049 ·Status: RECRUITING
-
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
NCT05687188 ·Status: RECRUITING
-
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
NCT02072616 ·Status: TERMINATED ·Phase: NA
-
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma
NCT01219829 ·Status: COMPLETED
-
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
NCT04525209 ·Status: UNKNOWN
-
Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas
NCT02817308 ·Status: UNKNOWN ·Phase: NA
-
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
NCT00830557 ·Status: RECRUITING
-
A Study of Pancreatic Cancer in Xenografts From Liver Metastases
NCT01774643 ·Status: COMPLETED
-
ctDNA Assay in Patients With Resectable Pancreatic Cancer
NCT05052671 ·Status: RECRUITING